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Acute liver failure (ALF) is characterized by a sudden and severe deterioration of liver
function, typically mirrored by a marked increase of the international normalized ratio
(INR) and hepatic encephalopathy (HE). Due to various possible causes hepatocytes get
damaged via either apoptotic or necrotic pathways. Anticipating the natural prognosis of a
patient with ALF is one of the most challenging tasks in hepatology critical care. Important
factors that influence the chance of spontaneous recovery are the underlying etiology of
acute liver failure, the acuity of disease, and the severity of HE. Once an estimation of
the prognosis in the individual patient has been made, this quickly has to be integrated in
the discussion whether high-urgency liver transplantation is necessary and justifiable. This
decision has to cover several medical, social, and organizational issues. Well organized liver
transplantation programs around the world have achieved an impressive improvement of
the 1 year survival rate in ALF from around 40% without transplantation up to nearly 80%
with transplantation. The recent debate on whether severe acute alcoholic hepatitis could
represent a new candidate eligible for high-urgency liver transplantation shows that the
topic is still open for discussion.
Keywords: acute hepatitis, biomarker, emergency liver transplantation, hepatic encephalopathy, hepatic failure,
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INTRODUCTION
The overall incidence of acute liver failure (ALF) in developed
countries is estimated to be 1–6 per million people every year
(Bower et al., 2007; Bernal et al., 2010). Emergency liver trans-
plantation (ELT) is a potentially life-saving procedure in patients
with ALF, but carries relevant long-term morbidity and mortal-
ity. Appropriate selection of patients for ELT therefore requires
tools allowing to accurately prognosticate spontaneous recov-
ery (Renner, 2007). The prediction of outcome in an individual
patient with ALF is among the most challenging tasks in hepatol-
ogy critical care. Many retrospective observational studies have
tried to identify particular clinical and laboratory markers or
prognostic models capable of predicting prognosis and need of
ELT. This article addresses some of the questions that arise when
facing a patient who progressively deteriorates from severe acute
hepatitis to ALF.
ACUTE OR ACUTE-ON-CHRONIC—DIFFICULT TO
DISTINGUISH
A deteriorating liver function that comes to attention for the
first time often triggers the assumption of an ALF. But by def-
inition, ALF implies the absence of chronic liver disease (Trey
and Davidson, 1970; Bernal et al., 2010; Lee et al., 2011), and the
majority of patients that present with worsening liver function
suffer from acute-on-chronic liver failure (i.e., an acute deteri-
oration superimposed on chronic liver disease). Non-alcoholic
and alcoholic fatty liver disease with varying degrees of fibrosis
are among the most common causes of pre-existing liver injury
in those patients. Patients with acute-on-chronic liver failure
can often be identified by thorough history taking and phys-
ical examination. The role of abdominal ultrasound is more
complex. Undoubtedly, ultrasound will detect overt liver cirrho-
sis presenting with reduced liver volume, irregular liver surface,
distorted liver veins, and nodular liver parenchyma (Caselitz,
1999). But cirrhotic parenchymal changes can be difficult to
detect in steatosis, and signs of portal hypertension may also
develop in subacute liver failure. Furthermore, acute hepati-
tis triggers inflammatory infiltration, hepatocyte swelling, and
early regenerative fibrotic parenchymal changes. These processes
have been shown to increase liver stiffness when measured by
transient elastography and newer ultrasound technologies and
thereby can hamper the distinction between acute and chronic
liver injury (Arena et al., 2008; Sagir et al., 2008; Dechêne et al.,
2010).
A transjugular liver biopsy might aid in confirming cer-
tain ALF etiologies (Lee et al., 2011) and even in defin-
ing the degree of liver necrosis (Beckmann et al., 2009). But
liver biopsy is not recommended and probably of minor help
in distinguishing acute-on-chronic from acute liver failure.
Moreover, it remains an open question which degree of pre-
existing liver injury should be regarded as a contraindication
for ELT. Whereas a significant chronic component of deterio-
rated liver function is generally regarded a contraindication for
ELT, there are at least three exceptions to this rule: ALF in
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autoimmune hepatitis, Wilson’s disease, and Budd-Chiari syn-
drome can arise from a relapsing or chronic course of disease.
Those patients are suitable ELT candidates despite cirrhotic hep-
atic changes.
ROLE OF HEPATIC ENCEPHALOPATHY AND ETIOLOGY
IN OUTCOME PREDICTION
Not too surprisingly, the prospective observational study by the
US ALF Study Group underlined the major prognostic role of
hepatic encephalopathy (HE) and etiology in ALF. HE grade pos-
sibly reflects the degree of cerebral edema. Whereas ALF patients
with a baseline HE grade 1/2 had a transplant-free 21-day sur-
vival of 52%, this was only 33% in patients initially presenting
with HE grade 3/4 (Ostapowicz et al., 2002). A hyperacute course
(interval from icterus to encephalopathy <7 days) of liver fail-
ure (O’Grady et al., 1989) that is typically seen in acetaminophen,
hepatitis A or herpes simplex virus (Graham et al., 2009; Bernal
et al., 2010) is associated with a sudden rise in international nor-
malized ratio (INR), an increased risk of cerebral edema and a
rather high transplant-free survival rate. A subacute course (inter-
val from icterus to encephalopathy >21 days) (O’Grady et al.,
1989), as seen in indeterminate ALF implies a low transplant-free
survival rate despite initially moderate increases in INR and low
rates of cerebral herniation (Ostapowicz et al., 2002; Hadem et al.,
2008; Bernal et al., 2010).
Data from Europe and the US ALF Study Group show
that transplant-free survival rates in ALF patients are strongly
associated with the underlying ALF etiology: 60–80% in
acetaminophen-induced ALF, 30–40% in severe acute hepatitis B,
10–20% in indeterminate ALF, 20–50% in non-acetaminophen
drug-induced ALF, 0–20% in Wilson’s disease and around
70–80% in amanita ingestion (Ostapowicz et al., 2002; Escudié
et al., 2007; Hadem et al., 2008). Only 10% of patients with
drug-induced hepatitis progress to ALF which then implies a bad
prognosis even after the provoking medication has been stopped
(Andrade et al., 2005; Reuben et al., 2010). Phenprocoumon,
a coumadin derivate used in Germany can cause drug-induced
ALF associated with low transplant-free survival rates (Hadem
et al., 2008; Canbay et al., 2009). Mortality rate in ALF caused
by hepatitis E is assumed to be 8–11% in Western countries,
but can be as high as 50% when ELT is not available, and
may also be higher when acquired during pregnancy (Bernuau
et al., 2008). Pregnancy-related ALF is a heterogeneous disease
entity which has not sufficiently been studied. A recent obser-
vational study reported on 54 patients (18 acute fatty liver of
pregnancy, 32 eclampsia-associated) of whom 13% died and 7%
received ELT (Westbrook et al., 2010). Budd-Chiari syndrome
and early graft dysfunction are among other causes of ALF with
high risk of a fatal outcome. Although transjugular intrahepatic
portosystemic shunting (TIPS) has undoubtedly decreased the
case fatality rate of Budd-Chiari syndrome presenting with ALF,
data on the use of TIPS in this setting are still scarce. In the
important paper on TIPS in Budd-Chiari syndrome by Garcia-
Pagan et al. only 9/124 (7%) had ALF prior to TIPS, only 27/124
(22%) received TIPS due to (acute or chronic) liver failure, and
a significant proportion of these patients needed ELT or died
(Garcia-Pagán et al., 2008).
PROGNOSTIC MARKERS IN ACUTE LIVER FAILURE
RATIONALE BEHIND PROGNOSTICMARKERS
Many prognostic markers have been proposed to overcome the
prognostic uncertainty that is a major problem in the early phase
of ALF. One common approach is to deduce the outcome from
the degree of aminotransferase increase. These enzymes are—like
many other components of the hepatocellular content—released
into the circulation in apoptosis and necrosis. However, there is
no reliable association between aminotransferases and outcome.
Ischemic hepatitis and acetaminophen toxicity regularly present
with huge aminotransferase increases, but often are associated
with favorable prognosis. Another approach is to measure serum
markers of liver regeneration (e.g., alpha-fetoprotein, cytokines,
growth factors, and also phosphate) to get an idea of the hep-
atic regenerative capacity. These parameters have mainly been
studied in patients with hyperacute liver failure in the setting of
acetaminophen toxicity. A reasonable way to quantify the sever-
ity of liver damage is to extrapolate the course of ALF according
to serial hepatocellular function measurements. Synthetic liver
capacity is best observed by tracking the INR that reflects the syn-
thesis of clotting factors II, V, VII, and X. Rapid deteriorations can
be recognized by decreases of factor V due to its short half time of
12–15 h. Detoxification liver capacity can be monitored by biliru-
bin, ammonia, indocyanin green, and other serum parameters.
Many of these parameters have been incorporated in a number
of prognostic criteria in an attempt to predict ALF outcome as
accurately as possible.
ALPHA-FETOPROTEIN
Among the early investigations on prognostic markers in ALF
is that of Murray-Lyon et al. from King’s College Hospital.
Sixty-four patients with fulminant hepatic failure were examined
regarding their serum alpha-fetoprotein (AFP) levels. AFP levels
>50 ng/ml were observed in 48% of the 23 survivors, but only
in 10% of the 41 ALF patients with a fatal outcome (Murray-
Lyon et al., 1976). In a subsequent study on 239 patients with
acetaminophen intoxication, a threshold AFP of ≥3.9µg/l on
day + 1 after peak ALT to identify nonsurvivors had a sensitiv-
ity of 100% and a specificity of 74% (Schmidt and Dalhoff, 2005).
A retrospective analysis of 206 patients from the US ALF study
(80 acetaminophen, 30 indeterminate) showed that an AFP day
3-to-day1 ratio >1 predicted survival with a sensitivity of 65%
and a specificity of 84% (Schiødt et al., 2006).
LACTATE
Arterial blood lactate levels can be measured rapidly by point-of-
care testing and reflect both increased production from peripheral
tissues and the injured liver and reduced clearance from the cir-
culation as a consequence of impaired hepatic metabolic capacity
(Bernal, 2010). In a mixed prospective/retrospective study of over
200 patients with acetaminophen-induced ALF, high blood lactate
levels were found to be closely related to a fatal outcome (Bernal
et al., 2002). Subsequent studies found arterial lactate (baseline or
12 h after admission) to be associated strongly and independently
with death or transplantation in both acetaminophen and non-
acetaminophen-induced ALF (Macquillan et al., 2005; Schmidt
and Larsen, 2006; Hadem et al., 2008; Bernal et al., 2010). Baseline
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lactate levels were higher (median 4.7 vs. 2.9mmol/L) and steadily
increased in ALF patients with an unfavorable outcome (Hadem
et al., 2008). Others have argued that lactate lacks the specificity
required to a sole criterion for ELT listing (Schmidt and Larsen,
2010). Different views on the prognostic value of lactate levels in
ALF are likely to reflect variability in the timing and degree of
fluid resuscitation in early ALF management. The greatest prog-
nostic value will therefore be gained from those patients in whom
no correction of initially high levels occurs following volume
resuscitation, and these patients should probably be considered
for ELT (Bernal, 2010).
INR
A number of studies illustrating the time course of daily INR val-
ues nicely show that a single INR level at the onset of HE (i.e., the
overt manifestation of ALF) do not necessarily mirror the severity
of liver damage and prognosis. This is particularly true for hyper-
acute ALF courses such as in acetaminophen or amanita toxicity
(Escudié et al., 2007; Schmidt and Larsen, 2007). It is particu-
larly in the subacute ALF setting that sustained elevations of INR
become important for decision-making.
FACTOR V AND CLICHY-VILLEJUIF CRITERIA
Early investigations of factor V in patients with fulminant hep-
atitis B have proven this marker to be an independent predictor
of survival (Bernuau et al., 1986). Factor V, HE, and patients’ age
were later incorporated into the so called Clichy-Villejuif crite-
ria which have been established particularly in France (Bismuth
et al., 1995), but also form part of the German transplantation
law (Richtlinien Organtransplantation, 2011). An unfavorable
outcome can be expected in >90% of cases with HE plus a fac-
tor V level less than 20% of normal (in patients younger than
30 years of age) or less than 30% of normal (in patients older
than 30 years of age), respectively (Table 1) (Bismuth et al.,
1995).
AMMONIA
In ALF, ammonia escapes hepatic metabolism, leading to high
arterial ammonia concentrations. Clemmesen et al. showed that
ALF patients who developed clinical signs of cerebral herniation
(n = 14 out of 44) had higher arterial plasma ammonia levels
compared to those who did not (230 vs. 118µmol/L, p < 0.001)
(Clemmesen et al., 1999). This finding was later validated in a
group of 165 patients with ALF and HE. An arterial ammonia
level greater than 100µmol/L was an independent risk factor
for severe HE (sensitivity 59%, specificity 78%) and intracranial
hypertension (sensitivity 73%, specificity 44%). The combination
of arterial ammonia with the Model of End-stage Liver Disease
(MELD) further increased specificity in prediction of HE (Bernal
et al., 2007).
Table 1 | Clichy-Villejuif criteria for non-acetaminophen ALF.
Hepatic encephalopathy AND
Factor V <20%, if <30 years of age OR
Factor V <30%, if >30 years of age
PHOSPHATE
Schmidt and Dalhoff published data on serum phosphate levels
in 95 patients with severe acetaminophen poisoning. Phosphate
concentrations were significantly higher in nonsurvivors than in
survivors 48 h after overdose. A threshold phosphate concen-
tration of 1.2mmol/L at 48–96 h after overdose specifically and
sensitively identified a group of patients with very little chance
of spontaneous survival. The phosphate criteria had higher pre-
dictive values than the King’s College criteria (KCC). The authors
proposed that hyperphosphatemia is caused by renal dysfunction
in the absence of hepatic regeneration, whereas the latter appears
to be associated with lowering of serum phosphate. Possible lim-
itations of this study were the relatively low numbers of patients
with HE (n = 30) and a fatal outcome (n = 16) (Schmidt and
Dalhoff, 2002).
KING’S COLLEGE CRITERIA
The most commonly used prediction models are the KCC
that were initially based on a retrospective study on 588
patients with ALF managed medically during 1973–1985. The
model was validated in an independent cohort of 175 ALF
patients treated between 1986 and 1987. The KCC distinguish
between acetaminophen and non-acetaminophen-induced ALF
and include pH, HE, INR, creatinine, etiology, bilirubin, age,
and acuity of symptom onset (Table 2) (O’Grady et al., 1989).
Several case series and meta-analyses have confirmed that KCC
have clinically acceptable specificity of 80–90%, with survival
without transplantation in patients meeting criteria of less than
15%. However, sensitivity of KCC has been reported to be as low
as 60–70%, indicating that KCC may fail to detect patients facing
a fatal outcome without ELT (Anand et al., 1997; Hadem et al.,
2008; Bernal et al., 2010; Craig et al., 2010; McPhail et al., 2010).
Despite this draw-back, KCC form the basis for ELT registration
in many countries (Neuberger et al., 2008; Bernal et al., 2010;
Richtlinien Organtransplantation, 2011).
MODEL OF END-STAGE LIVER DISEASE (MELD) SCORE
Originally developed for allocation in patients with chronic liver
disease, the MELD score has been evaluated as prognostic marker
Table 2 | King’s college criteria.
ACETAMINOPHEN-INDUCED ALF
Arterial pH <7.3 (regardless of HE)
OR all 3 of the following
– INR >6.5
– Creatinine >300µmol/l
– HE grade 3–4
NON-ACETAMINOPHEN-INDUCED ALF
INR >6.5 (regardless of HE)
OR 3 of 5 of the following (regardless of HE)
– Age <10 or >40 years
– Etiology: indeterminate, drug-induced
– Time interval icterus to encephalopathy > 7 days
– INR >3.5
– Bilirubin >300µmol/l
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in ALF. Yantorno et al. investigated 64 adult ALF patients of mixed
etiology and found MELD to provide better predictive value than
KCC in a Cox model, defining aMELD of 30 as prognostic cut-off
(Yantorno et al., 2007).
Another study examined MELD in 124 patients with
acetaminophen-induced ALF. A threshold MELD score of 33 on
the day after the onset of HE had a sensitivity of 60%, and a
specificity of 69% in predicting death. However, the discrimi-
native power of MELD score was not superior to that of INR
alone or of the KCC (Schmidt and Larsen, 2007). Katoonizadeh
et al. evaluated 99 patients with non-acetaminophen-induced
ALF and found the best MELD cut-off to be >35 (sensi-
tivity 86%, specificity 75%). Again, MELD was not superior
to KCC (Katoonizadeh et al., 2007). A retrospective observa-
tional study on 134 German ALF patients of mixed etiology
showed MELD to be an independent prognostic factor with
a median MELD of 33 in the fatal prognostic group (Canbay
et al., 2009). Another retrospective study on 102 ALF patients
of mixed etiology from northern Germany demonstrated that
MELD-based outcome prediction was comparable to that by KCC
(Hadem et al., 2008). Finally, a modification of classic MELD
by substituting the level of the M65 epitope of cytokeratin-18
(CK 18) for bilirubin, significantly improved the positive pre-
dictive value in a cohort of mainly 68 acetaminophen-induced
ALF (Bechmann et al., 2010). The M65 epitope of CK 18 is
exposed on all intact and fragmented CK18 variants released
from destroyed hepatocytes, has been studied in several chronic
liver disease entities (Bantel et al., 2001), and might thus allow
a better quantification of liver damage in ALF (Volkmann et al.,
2008).
BILIRUBIN-LACTATE-ETIOLOGY (BiLE) SCORE
Bilirubin-Lactate-Etiology (BiLE) score was empirically devel-
oped based on 102 ALF patients of mixed etiology (predomi-
nantly indeterminate ALF) from northern Germany and found
to be slightly superior to KCC, MELD, and SAPS-III in predicting
death or need of ELT with a sensitivity of 79% and a specificity of
84%. BiLE score is calculated by adding bilirubin and lactate with
an etiology-specific summand (Table 3) (Hadem et al., 2008). In
an external retrospective evaluation of BiLE in 422 consecutive
ALF patients from the UK (57% with acetaminophen-induced
ALF), BiLE lacked sensitivity (55%), but had a good specificity
of 89% (Bernal et al., 2009). As with other models, BiLE score has
therefore not yet proven superiority over established models such
as KCC, and it appears premature to base transplant decisions on
BiLE at this point of time.
Table 3 | Bilirubin Lactate Etiology (BiLE) score.
BiLE score =
Bilirubin (µmol/l)/100
+ Lactate (mmol/l)
+ 4 [in case of indeterminate ALF, Budd-Chiari syndrome or
phenprocoumon toxicity]
− 2 [in case of acetaminophen toxicity]
+ 0 [in case of any other ALF etiology]
RECENT ADVANCES IN ALF OUTCOME PREDICTION
An interesting prognostic scoring model for non-acetaminophen
ALF has been proposed by colleagues from Japan. Four param-
eters (unfavorable etiology, HE grade 3/4, presence of systemic
inflammatory response syndrome, and ratio of total to direct
bilirubin >2) were evaluated retrospectively in 80 patients, and
prospectively validated in another 26 patients on days 1, 4, 8,
and 15. The scoring model predicted 2-week survival rates with
high sensitivity and specificity, when all four time points of
scoring were taken into account. However, the earliest score on
day 1 which is the one of greatest clinical interest tended to
underestimate the probability of a fatal outcome (Miyake et al.,
2005).
As in liver cirrhosis, there has been a growing interest in
applying scores of multiple organ dysfunction to ALF patients.
Sequential Organ Failure Assessment (SOFA) score is an ordinal
variable that covers six organ systems and has been established
as dynamic disease severity measurement tool in intensive care
(Vincent et al., 1996). Craig et al. investigated SOFA in 138
acetaminophen overdoses (only 48% with HE) and found that
SOFA provided superior outcome discrimination compared to
MELD. The authors stated, however, that due to limited speci-
ficity, SOFA would not be capable of replacing KCC as definite
listing criteria (Craig et al., 2012). Moreover, organ dysfunction
as documented by SOFA, typically develops>72 h following ALF
onset and therefore does probably not represent a very early
predictive tool.
Angiopoietin-2 (Angpt2), a mediator of endothelial activation
and capillary leakage, is known to be up-regulated in sepsis, but
its role in ALF has just recently been investigated. Angpt2 serum
levels were examined in 37 patients with ALF of mixed etiology
and 20 healthy controls. Angpt2 revealed to be a predictor of the
composite end-point of death or ELT and correlated strongly with
surrogate markers of organ dysfunction. Immunohistological
studies showed that Angpt2 was upregulated in ALF explants
(Hadem et al., 2012). Angpt2 might therefore explain the regu-
larly observed sepsis-like clinical picture of ALF patients and also
serve as a marker of impending multiple organ failure.
ACUTE LIVER FAILURE—WHOM ANDWHEN TO
TRANSPLANT IN CLINICAL PRACTICE
Current criteria for selection of patients with ALF for ELT are far
from being perfect (Renner, 2007). The ideal means for identifi-
cation of patients who are likely to benefit from ELT still remains
controversial (Bernal et al., 2010). A patient who would have sur-
vived with medical management, incorrectly transplanted will be
subjected to unnecessary surgery, life-long immunosuppression,
and an increased risk of death. Furthermore, a graft that could
be used in a more appropriate candidate will be lost (Bernal,
2010). Decisions regarding ELT have to be made early-on dur-
ing the course of ALF because of impending complications such
as cerebral herniation or multiple organ failure. In a retrospec-
tive study from King’s College Hospital of 310 ALF patients listed
for ELT, the median time from listing to ELT was 1 day. However,
24% of listed patients did not undergo surgery, mainly because of
death on the waiting list at a median of 2 days after listing (Bernal
et al., 2009). Similar observations were made in the US ALF study
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cohort with a median time from listing to ELT of 3.5 days and a
median time from admission to death of 5 days (Ostapowicz et al.,
2002).
The difficult questions whom and when to perform ELT in an
individual patient are best answered in a multiple step approach.
First, the focus is on ALF etiology and HE grade to ensure
that the ELT candidate will have a grim prognosis without ELT.
Other predictive markers such as acuity of symptom onset, sus-
tained increase in INR, or persisting elevation of lactate after
adequate fluid resuscitation can be incorporated in the deci-
sion. Sometimes, daily ultrasoundmonitoring of progressing liver
dystrophy can complete the physician’s judgment on which ther-
apeutic path to follow. Established prognostic models such as
the KCC and the Clichy Villejuif criteria are certainly of value.
All these factors should rather be regarded as pieces of a mosaic
than definite criteria. It is rather the rule than an exception
that a clear-sighted decision has to rely on a certain amount
of physician’s gut feeling. For example, slow clinical deteriora-
tion, moderately elevated INR and undulating bilirubin levels
in a young female with subacute indeterminate ALF should not
deceive the team about her likely bad prognosis. On the other
hand, a patient with acetaminophen-induced ALF and hyperacute
clinical presentation may have a high spontaneous survival rate
even though experiencing advanced stages of disease (Schmidt
and Larsen, 2010). A useful summary of the UK criteria for regis-
tration as high-urgent ELT candidate has recently been published
by Neuberger et al. (2008).
Second, potential contraindications against ELT have to be
excluded. Among them are (1) advanced biological patient age,
(2) pre-existing chronic comorbidities (major psychiatric disor-
ders probably influencing patient’s post-transplant compliance,
heavy alcohol abuse, cardiopulmonary disorders), (3) unfavor-
able severity of pretransplant illness (reflected by high-dose
vasopressor support or multiple organ dysfunction), and (4)
secondary ALFs in the setting of severe sepsis or generalized
ischemia (e.g., after cardiopulmonary resuscitation). Patients
with acetaminophen-induced ALF are at high risk of developing
pre-ELT complications. Additionally, ELT recipients >50 years
face a doubled postoperative mortality (Bernal et al., 2009).
Third, the quality of the liver graft influences post-ELT out-
come and has to be matched in each individual case. It is very
demanding to find the right balance between risking delay of ELT
until an ideal graft is available and early acceptance of a subopti-
mum graft that might be associated with a poor outcome (Bernal
et al., 2009, 2010).
SEVERE ACUTE ALCOHOLIC HEPATITIS—A NEW
CANDIDATE FOR EMERGENCY LIVER
TRANSPLANTATION?
Mathurin et al. recently reported on 26 patients with a first
episode of severe alcoholic hepatitis that were not responding to
medical therapy and selected to receive ELT. Six-month survival
was markedly improved compared with patients not receiving
ELT (78% vs. 24%). Three out of 26 patients (12%) experi-
enced alcohol relapse (Mathurin et al., 2011). As these patients
were highly selected involving the whole primary care team and
focusing on the patient’s social background, it remains open, if a
broader consideration of alcoholic hepatitis for ELT would result
in similarly good outcomes. The current discussion about alco-
holic hepatitis as potential candidate for ELT focuses on the issue
of justice among liver graft recipients, possible biases in selecting
suitable candidates, the 12% relapse rate, the rather arbitrarily
defined 6-month abstinence rule, and the high rate of periop-
erative infectious complications (Brown, 2011; John and Chung,
2012; Moreno et al., 2012).
CONCLUSION
In conclusion, selecting the ALF patient in need of ELT, deter-
mining the right point of time for wait-listing, and matching
patient and liver graft remains challenging. This demands expe-
rience as well as a high grade of suspicion. Available prognostic
parameters and models can be of help, but should be regarded
as pieces of a mosaic rather than definite therapeutic algo-
rithms. Proper management of ALF patients have now achieved
an increase in overall survival rates from 40% without availability
of ELT to over 80% post ELT (Ostapowicz et al., 2002; Lee et al.,
2011).
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